Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2017 07/20/2017 07/21/2017 07/24/2017 07/25/2017 Date
2.42(c) 2.37(c) 2.4(c) 2.34(c) 2.34(c) Last
137 936 63 744 101 172 143 243 176 266 Volume
+1.26% -2.07% +1.27% -2.50% 0.00% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
More about the company
Latest news on PULMATRIX INC
06/26 PULMATRIX INC : Innovative Pulmatrix Drug Offers New Hope for Fighting Fungal Lu..
06/15 PULMATRIX, INC. : Change in Directors or Principal Officers, Other Events, Finan..
06/15 PULMATRIX : Amit D. Munshi Joins Pulmatrix's Board of Directors
06/13 ZACKS INITIATES ON PULMATRIX (NASDAQ : Pulm)
06/13 PULMATRIX, INC. : Entry into a Material Definitive Agreement, Other Events, Fina..
06/13 PULMATRIX : Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned s..
06/09 PULMATRIX, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/18 PULMATRIX : Receives Key US Patent for its Inhaled Drug for COPD
05/18 PULMATRIX INC : Today's Research Reports on Biotech Stocks to Watch: Pulmatrix a..
05/17 PULMATRIX INC : Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Pote..
More news
Sector news : Bio Therapeutic Drugs
10:51a Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJCELGENE : Settles Lawsuit Over Improper Promotion of Cancer Drugs
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/23RECAP 6/23 +Chatter: $ETSY $SFM $UPS $ABY $VRX $PTLA $PULM -Chatter: $WFM
1
06/23$PULM Pulmatrix receives USPTO Notice of Allowance for a new patent related t.. 
06/16Amit D. Munshi Joins Pulmatrix's Board of Directors  
06/15 ? Pulmatrix Inc (NASDAQ:PULM) Is Once Again Dramatically Undervalued via ?
1
06/13Zacks Initiates on Pulmatrix (NASDAQ:PULM)  
More tweets
Qtime:7
News from SeekingAlpha
06/13 Pulmatrix in-licenses kinase inhibitors from Janssen subsidiary for use with ..
06/13 PREMARKET GAINERS AS OF 9 : 05 am
05/17 Pulmatrix up 21%
05/17 Midday Gainers / Losers
05/17 HEALTHCARE GAINERS / LOSERS AS OF 1 : 00 am
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
Terrance G. McGuire Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC296.61%45
AMGEN23.72%133 026
CELGENE CORPORATION17.87%106 536
GILEAD SCIENCES2.97%96 358
REGENERON PHARMACEUTICALS39.87%54 575
VERTEX PHARMACEUTICALS119.86%40 342